Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Aug;26(8):e1314-e1319.
doi: 10.1002/onco.13762. Epub 2021 Apr 22.

Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen

Alessandro Passardi  1 , Manlio Monti  1 , Caterina Donati  2 , Flavia Foca  3 , Flavia Pagan  3 , Ilario Rapposelli  1 , Silvia Ruscelli  1 , Giulia Bartolini  1 , Martina Valgiusti  1 , Laura Matteucci  1 , Francesco Sullo  1 , Stefania Sbaffi  2 , Laura Crudi  2 , Giovanni Luca Frassineti  1 , Carla Masini  2
Affiliations
Observational Study

Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen

Alessandro Passardi et al. Oncologist. 2021 Aug.

Abstract

Lessons learned: The use of sodium levofolinate (Na-Lev) is safe in combination with continuous infusion 5-fluorouracil in patients with gastrointestinal tumors treated with the FOLFIRI regimen. A comparison with calcium levofolinate (Ca-Lev) showed a similar toxicity profile. The advantages of Na-Lev over Ca-Lev might be the faster drug preparation and the shorter time of drug administration.

Background: The objectives of this study were to compare the safety profiles of sodium levofolinate (Na-Lev) and calcium levofolinate (Ca-Lev) in combination with 5-fluorouracil (5-FU) in the FOLFIRI regimen and to measure the organizational impact of the introduction of Na-Lev on drug production and administration.

Methods: The study opened in November 2015 and closed in August 2019. Patients with gastrointestinal cancers who were candidates for treatment with the FOLFIRI regimen were included in this nonrandomized study. Age ≥18 years, life expectancy >3 months, adequate bone marrow reserve, adequate hepatic and renal function, and an ECOG performance status of 0-2 were required. Patients in the Ca-Lev arm received a 2-hour infusion of Ca-Lev followed by 5-FU, whereas those in the Na-Lev arm received Na-Lev and 5-FU administered in a single 48-hour pump.

Results: Sixty patients were enrolled, 30 in each arm. Patient characteristics were balanced. Grade (G)1-2 adverse events occurred in 18 (60.0%) and 19 (63.4%) patients of Na-Lev and Ca-Lev cohorts, respectively, whereas G3-4 adverse events occurred in 12 (40.0%) and 11 (36.6%) patients, respectively. The use of Na-Lev enabled us to save approximately 13 minutes for drug preparation and 2 hours for treatment administration, per patient per cycle.

Conclusion: Na-Lev showed a reassuring toxicity profile and a favorable impact on drug preparation and administration.

Trial registration: ClinicalTrials.gov NCT04680104.

Keywords: Calcium levofolinate; FOLFIRI; Sodium levofolinate.

PubMed Disclaimer

References

    1. Lokich JJ, Ahlgren JD, Gullo JJ et al. Prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A mid‐Atlantic Oncology Programme Study. J Clin Oncol 1989;7:425–432. - PubMed
    1. Schmoll HJ, Kohne CH Lorenz M et al. Weekly 24‐h infusion of high‐dose (HD) 5‐fluorouracil with or without folinic acid (FA) vs. Bolus 5‐FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC GOTCCG and the AIO. Proc Am Soc Clin Oncol 2000;19:935a.
    1. Jäger E, Klein O, Wchter B et al. High‐dose 5‐fluorouracil (5‐FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5‐FU treatment: Result of a phase II study. Eur J Cancer 1995;31:1717. - PubMed
    1. Hartmann JT, Köhne CH, Schmoll HJ et al. Is continuous 24‐hour infusion of 5‐fluorouracil plus high‐dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study. Oncology 1998;55:320–325. - PubMed
    1. Ardalan B1, Chua L, Tian EM et al. A phase II study of weekly 24‐hour infusion with high‐dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991;9:625–630. - PubMed

Publication types

MeSH terms

Associated data